These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 19590782)

  • 1. Three-dimensional structure-activity relationship study of belactosin A and its stereo- and regioisomers: development of potent proteasome inhibitors by a stereochemical diversity-oriented strategy.
    Yoshida K; Yamaguchi K; Mizuno A; Unno Y; Asai A; Sone T; Yokosawa H; Matsuda A; Arisawa M; Shuto S
    Org Biomol Chem; 2009 May; 7(9):1868-77. PubMed ID: 19590782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of 2,3- and 3,4-methanoamino acid equivalents with stereochemical diversity and their conversion into the tripeptide proteasome inhibitor belactosin a and its highly potent cis-cyclopropane stereoisomer.
    Yoshida K; Yamaguchi K; Sone T; Unno Y; Asai A; Yokosawa H; Matsuda A; Arisawa M; Shuto S
    Org Lett; 2008 Aug; 10(16):3571-4. PubMed ID: 18642830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of boron peptide analogues of Belactosin C as proteasome inhibitors.
    Nakamura H; Watanabe M; Ban HS; Nabeyama W; Asai A
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3220-4. PubMed ID: 19428245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of the stabilized analogs of belactosin A with the unnatural cis-cyclopropane structure.
    Kawamura S; Unno Y; Asai A; Arisawa M; Shuto S
    Org Biomol Chem; 2013 Oct; 11(38):6615-22. PubMed ID: 23986389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action.
    Kawamura S; Unno Y; List A; Mizuno A; Tanaka M; Sasaki T; Arisawa M; Asai A; Groll M; Shuto S
    J Med Chem; 2013 May; 56(9):3689-700. PubMed ID: 23547757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enantioselective total syntheses of belactosin A, belactosin C, and its homoanalogue.
    Larionov OV; de Meijere A
    Org Lett; 2004 Jun; 6(13):2153-6. PubMed ID: 15200308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclopropane-based stereochemical diversity-oriented conformational restriction strategy: histamine H3 and/or H4 receptor ligands with the 2,3-methanobutane backbone.
    Watanabe M; Kobayashi T; Hirokawa T; Yoshida A; Ito Y; Yamada S; Orimoto N; Yamasaki Y; Arisawa M; Shuto S
    Org Biomol Chem; 2012 Jan; 10(4):736-45. PubMed ID: 22120611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological activity of simplified belactosin C analogues.
    de Meijere A; Korotkov VS; Lygin AV; Larionov OV; Sokolov VV; Graef T; Es-Sayed M
    Org Biomol Chem; 2012 Aug; 10(31):6363-74. PubMed ID: 22735304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixing of peptides and electrophilic traps gives rise to potent, broad-spectrum proteasome inhibitors.
    Verdoes M; Florea BI; van der Linden WA; Renou D; van den Nieuwendijk AM; van der Marel GA; Overkleeft HS
    Org Biomol Chem; 2007 May; 5(9):1416-26. PubMed ID: 17464411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of lipopeptides for inhibiting 20S proteasomes.
    Basse N; Papapostolou D; Pagano M; Reboud-Ravaux M; Bernard E; Felten AS; Vanderesse R
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3277-81. PubMed ID: 16630721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates.
    Zhu Y; Zhao X; Zhu X; Wu G; Li Y; Ma Y; Yuan Y; Yang J; Hu Y; Ai L; Gao Q
    J Med Chem; 2009 Jul; 52(14):4192-9. PubMed ID: 19537716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome.
    Momose I; Umezawa Y; Hirosawa S; Iinuma H; Ikeda D
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1867-71. PubMed ID: 15780623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of a series of 3,4-methanoarginines as side-chain conformationally restricted analogues of arginine.
    Watanabe M; Yamaguchi K; Tang W; Yoshida K; Silverman RB; Arisawa M; Shuto S
    Bioorg Med Chem; 2011 Oct; 19(20):5984-8. PubMed ID: 21917467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological activity of optimized belactosin C congeners.
    Korotkov VS; Ludwig A; Larionov OV; Lygin AV; Groll M; de Meijere A
    Org Biomol Chem; 2011 Oct; 9(22):7791-8. PubMed ID: 21946808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability.
    Staas DD; Savage KL; Sherman VL; Shimp HL; Lyle TA; Tran LO; Wiscount CM; McMasters DR; Sanderson PE; Williams PD; Lucas BJ; Krueger JA; Lewis SD; White RB; Yu S; Wong BK; Kochansky CJ; Anari MR; Yan Y; Vacca JP
    Bioorg Med Chem; 2006 Oct; 14(20):6900-16. PubMed ID: 16870455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of novel metalloproteinase inhibitors.
    Nakatani S; Ikura M; Yamamoto S; Nishita Y; Itadani S; Habashita H; Sugiura T; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
    Bioorg Med Chem; 2006 Aug; 14(15):5402-22. PubMed ID: 16621578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors.
    Sprangers R; Li X; Mao X; Rubinstein JL; Schimmer AD; Kay LE
    Biochemistry; 2008 Jul; 47(26):6727-34. PubMed ID: 18540636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclopropane-based conformational restriction of GABA by a stereochemical diversity-oriented strategy: identification of an efficient lead for potent inhibitors of GABA transports.
    Nakada K; Yoshikawa M; Ide S; Suemasa A; Kawamura S; Kobayashi T; Masuda E; Ito Y; Hayakawa W; Katayama T; Yamada S; Arisawa M; Minami M; Shuto S
    Bioorg Med Chem; 2013 Sep; 21(17):4938-50. PubMed ID: 23886812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Affinity labeling of the proteasome by a belactosin A derived inhibitor.
    Hasegawa M; Kinoshita K; Nishimura C; Matsumura U; Shionyu M; Ikeda S; Mizukami T
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5668-71. PubMed ID: 18801655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.